imiquimod has been researched along with Dermatitis Medicamentosa in 54 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.85) | 18.2507 |
| 2000's | 13 (24.07) | 29.6817 |
| 2010's | 36 (66.67) | 24.3611 |
| 2020's | 4 (7.41) | 2.80 |
| Authors | Studies |
|---|---|
| Hasbun, MT; Hussain, SH; Jones, KM; Schmidt, BAR; Zhong, CS | 1 |
| Trčko, K | 1 |
| Bassoy, EY; Caruso, A; Gabay, C; Goldstein, JD; Lemeille, S; Palomo, J; Rodriguez, E | 1 |
| Beylot-Barry, M; Costedoat, I; Dousset, L; Dutriaux, C; Gerard, E; Pham-Ledard, A; Prey, S; Vergara, R | 1 |
| Ku, CC; Lee, TL; Lin, YJ | 1 |
| Kamata, Y; Kosaka, R; Matsuda, H; Ogawa, H; Sakaguchi, A; Takahashi, N; Takamori, K; Tominaga, M; Umehara, Y | 1 |
| Chan, MYL; Kennedy, J; Oakley, A | 1 |
| Gonzalez, H; Haedersdal, M; Halldin, C; Sandberg, C; Sørensen, SS; Togsverd-Bo, K; Wennberg, AM; Wulf, HC | 1 |
| Favot, L; Jégou, JF; Lecron, JC; Mcheik, J; Morel, F; Pohin, M; Silvain, C; Vasseur, P; Venisse, N | 1 |
| Cabanillas, M; Monteagudo, B; Peña-López, S; Suárez-Magdalena, O | 1 |
| Palmer, G; Palomo, J; Rodriguez, E; Talabot-Ayer, D; Troccaz, S | 1 |
| Aberbigbe, O; Etzkorn, JR; Neal, DE; Smith, RJ | 1 |
| Borgia, F; Cannavò, SP; Giuffrida, R | 1 |
| Hooper, KM; Jensen, LE; Lian, LH; Milora, KA; Uribe-Herranz, M | 1 |
| Katz, KA; Swetman, GL | 1 |
| Furue, Y; Imura, C; Shichijo, M; Tsujii, K; Ueyama, A; Yamamoto, M; Yasui, K | 1 |
| Cohen, DN; Johnson, DB; Joseph, RW; Kelley, MC; Likhari, SS; Powers, JG; Shinn, L; Sosman, JA; Wallender, EK; Zwerner, JP | 1 |
| Argenziano, G; Drummond, A; Lallas, A; Longo, C; Moscarella, E; Piana, S; Pichler, J; Zalaudek, I | 1 |
| Ballester, I; Guijarro, J; Niveiro, M; Silvestre, JF | 1 |
| Ferrándiz, L; Márquez García, A; Ojeda Vila, T; Ríos Martín, JJ | 1 |
| Iversen, L; Johansen, C; Kragballe, K; Steiniche, T; Vinter, H | 1 |
| Altamura, D; Arkoumani, E; Hirbod, T; Simonacci, F; Verdolini, R | 1 |
| Clausen, BE; Ober-Blöbaum, JL; Pantelyushin, S; Wohn, CT | 1 |
| Bernard, FX; Blanchard, F; Boutet, MA; Favot, L; Frouin, E; Jégou, JF; Lecron, JC; Morel, F; Petit-Paris, I; Pohin, M; Rabeony, H; Ryffel, B; Togbe, D; Vasseur, P | 1 |
| Gaestel, M; Iversen, L; Johansen, C; Kragballe, K; Steiniche, T; Vinter, H | 1 |
| Hu, J; Sun, J; Wang, X | 1 |
| Chang, SE; Lee, MW; Lee, YJ; Rhee, do Y; Won, CH; Won, KH | 1 |
| Tsutsumi, R; Yamamoto, O; Yoshida, Y | 1 |
| Chong, HT; Cowin, AJ; Ibbetson, J; Kopecki, Z; Sidhu, S; Yang, GN | 1 |
| Borek, I; Clausen, BE; Farber, JM; Hedrick, MN; Kelsall, BL; Singh, SP; Singh, TP; Wolf, P; Zhang, HH | 1 |
| Altavilla, D; Anastasi, GP; Arcoraci, V; Bitto, A; Cutroneo, G; Ettari, R; Irrera, N; Lentini, M; Minutoli, L; Pallio, G; Pizzino, G; Scuruchi, M; Squadrito, F; Vaccaro, M | 1 |
| Ikizoglu, G; Kaya, TI; Tursen, U | 1 |
| Cavicchini, S; Gianotti, R; Muratori, S; Vezzoli, P | 1 |
| Bauza, A; Del Pozo, LJ; Martin, A; Saus, C | 1 |
| Taeron, C | 1 |
| Delgado Portela, M; García-Arpa, M; Rodríguez-Vázquez, M; Vera Iglesias, E | 1 |
| Heratizadeh, A; Kapp, A; Kupsch, E; Völker, B; Werfel, T; Wichmann, K | 1 |
| Raoulx, M; Skowron, C; Skowron, F | 1 |
| Crespo-Erchiga, A; Gómez-Moyano, E; Sanz Trelles, A; Vera Casaño, A | 1 |
| Heikkinen, AK; Susitaival, P | 1 |
| Lio, P; Mosher, JS | 1 |
| Adams, MP; Barry, GT; Feldman, R; Kulp, J; Levy, S; Wu, J | 1 |
| Cleaver, L; Knabel, P | 1 |
| Andres, K; Bichel, J; Ding, L; Herrera, E; Ruzicka, T; Sterry, W; Takwale, A; Thissen, MR | 1 |
| Ladd, DJ; Lin, R; Powell, DJ; Way, BV | 1 |
| Aeling, JL; Chapman, JT; Deeths, MJ; Dellavalle, RP; Zeng, C | 1 |
| Langtry, JA; Rajan, N | 1 |
| Barnetson, RS; Halliday, GM; Lee, JH; McKane, S; Ooi, T; Slade, HB; Zhuang, L | 1 |
| Kapembwa, M; Maslen, M; Taylor, CL | 1 |
| Dika, E; Fanti, PA; Miscial, C; Vaccari, S; Varotti, C | 1 |
| Ho, NT; Lansang, P; Pope, E | 1 |
| Cohen, JL; Greenberg, HL; Orengo, I; Rosen, T | 1 |
| Conant, MA; Friedman-Kien, AE; Gilson, RJ; Nayagam, AT; Owens, ML; Pietig, DC; Shupack, JL; Smith, MH; Swann, RV; Weber, JN | 1 |
| Salasche, S | 1 |
1 review(s) available for imiquimod and Dermatitis Medicamentosa
| Article | Year |
|---|---|
[Successful symptomatic treatment of epidermodysplasia verruciformis with imiquimod 5% cream].
Topics: Adjuvants, Immunologic; Administration, Topical; Aminoquinolines; Biopsy; Consanguinity; DNA Probes, HPV; Drug Administration Schedule; Drug Eruptions; Epidermodysplasia Verruciformis; Facial Dermatoses; Humans; Imiquimod; Male; Oligonucleotide Array Sequence Analysis; Papillomavirus Infections; Skin | 2010 |
6 trial(s) available for imiquimod and Dermatitis Medicamentosa
| Article | Year |
|---|---|
Photodynamic therapy is more effective than imiquimod for actinic keratosis in organ transplant recipients: a randomized intraindividual controlled trial.
Topics: Aged; Aminolevulinic Acid; Drug Eruptions; Facial Dermatoses; Female; Hand Dermatoses; Humans; Imiquimod; Keratosis, Actinic; Male; Middle Aged; Pain; Photochemotherapy; Photosensitizing Agents; Scalp Dermatoses; Treatment Outcome | 2018 |
Pharmacokinetics of daily self-application of imiquimod 3.75% cream in adult patients with external anogenital warts.
Topics: Adult; Aminoquinolines; Anus Diseases; Biotransformation; Condylomata Acuminata; Drug Eruptions; Female; Groin; Half-Life; Humans; Imiquimod; Immunologic Factors; Incidence; Male; Ointments; Perineum; Self Administration; Severity of Illness Index; Toll-Like Receptor 7; Warts; Young Adult | 2012 |
Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion.
Topics: Administration, Cutaneous; Adult; Aged; Aminoquinolines; Antineoplastic Agents; Carcinoma, Basal Cell; Drug Administration Schedule; Drug Eruptions; Female; Humans; Imiquimod; Male; Middle Aged; Occlusive Dressings; Skin Neoplasms; Treatment Outcome | 2002 |
Treatment of patch and plaque stage mycosis fungoides with imiquimod 5% cream.
Topics: Administration, Cutaneous; Adult; Aminoquinolines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Eruptions; Female; Humans; Imiquimod; Interferon Inducers; Male; Middle Aged; Mycosis Fungoides; Ointments; Pilot Projects; PUVA Therapy; Skin Neoplasms | 2005 |
Imiquimod-induced regression of actinic keratosis is associated with infiltration by T lymphocytes and dendritic cells: a randomized controlled trial.
Topics: Aged; Aminoquinolines; Biomarkers; Cell Movement; Dendritic Cells; Double-Blind Method; Drug Eruptions; Erythema; Female; Humans; Imiquimod; Immunophenotyping; Interferon Inducers; Keratosis; Male; Middle Aged; Photosensitivity Disorders; Skin; T-Lymphocyte Subsets; Treatment Outcome | 2006 |
A randomized, controlled, safety study using imiquimod for the topical treatment of anogenital warts in HIV-infected patients. Imiquimod Study Group.
Topics: Adjuvants, Immunologic; Administration, Topical; Adult; Aminoquinolines; CD4 Lymphocyte Count; Condylomata Acuminata; Double-Blind Method; Drug Eruptions; Female; HIV Infections; Humans; Imiquimod; Male; Middle Aged; Prospective Studies; Safety | 1999 |
47 other study(ies) available for imiquimod and Dermatitis Medicamentosa
| Article | Year |
|---|---|
Pemphigus-like eruption as a complication of molluscum contagiosum treatment with imiquimod in a 5-year-old girl.
Topics: Adjuvants, Immunologic; Child, Preschool; Drug Eruptions; Female; Humans; Imiquimod; Molluscum Contagiosum; Pemphigus | 2020 |
Imiquimod-associated erythema multiforme.
Topics: Aged; Drug Eruptions; Erythema Multiforme; Humans; Imiquimod; Male | 2020 |
IL-36 signaling in keratinocytes controls early IL-23 production in psoriasis-like dermatitis.
Topics: Administration, Cutaneous; Animals; Drug Eruptions; Female; Gene Deletion; Imiquimod; Interleukin-17; Interleukin-22; Interleukin-23; Interleukins; Keratinocytes; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Neutrophil Infiltration; Otitis Externa; Psoriasis; Receptors, Interleukin-1; Signal Transduction | 2020 |
Drug-induced bullous lichenoid eruption: a side effect of nivolumab triggered by the TLR agonist imiquimod.
Topics: Aged; Drug Eruptions; Drug Interactions; Humans; Imiquimod; Lichenoid Eruptions; Nivolumab | 2021 |
Development of an Economical DNA Delivery System by "Acufection" and its Application to Skin Research.
Topics: Alternative Splicing; Aminoquinolines; Animals; Cell Proliferation; Dendritic Cells; DNA; Drug Eruptions; Epidermal Cells; Female; Humans; Imiquimod; Interleukin-15; Keratinocytes; Membrane Glycoproteins; Mice, Inbred C57BL; Mice, Mutant Strains; Mice, Transgenic; Skin; Toll-Like Receptor 7; Transfection; Transgenes | 2017 |
Involvement of µ-opioid Receptors and κ-opioid Receptors in Itch-related Scratching Behaviour of Imiquimod-induced Psoriasis-like Dermatitis in Mice.
Topics: Aminoquinolines; Animals; Behavior, Animal; Disease Models, Animal; Drug Eruptions; Imiquimod; Male; Mice, Inbred C57BL; Narcotic Antagonists; Psoriasis; Receptors, Opioid, kappa; Receptors, Opioid, mu; Signal Transduction; Skin; Spinal Cord | 2017 |
Erythema multiforme triggered by imiquimod 5% cream.
Topics: Administration, Cutaneous; Aged; Antineoplastic Agents; Child; Drug Eruptions; Erythema Multiforme; Female; Humans; Imiquimod; Male; Skin Cream | 2017 |
Liver fibrosis is associated with cutaneous inflammation in the imiquimod-induced murine model of psoriasiform dermatitis.
Topics: Animals; Chemical and Drug Induced Liver Injury; Disease Models, Animal; Drug Eruptions; Imiquimod; Interferon Inducers; Liver Cirrhosis; Male; Mice, Inbred C57BL; Psoriasis | 2018 |
Erythema Multiforme Caused by Treatment With Topical Imiquimod 5% in a Patient With Gorlin Syndrome.
Topics: Administration, Topical; Antineoplastic Agents; Basal Cell Nevus Syndrome; Drug Eruptions; Erythema Multiforme; Female; Humans; Imiquimod; Middle Aged | 2018 |
The severity of imiquimod-induced mouse skin inflammation is independent of endogenous IL-38 expression.
Topics: Aminoquinolines; Animals; Cells, Cultured; Dermatitis; Disease Models, Animal; Drug Eruptions; Female; Imiquimod; Inflammation; Interleukin-1; Interleukins; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Severity of Illness Index; Skin | 2018 |
Cells to Surgery Quiz: July 2018.
Topics: Administration, Cutaneous; Aminolevulinic Acid; Antineoplastic Agents; Carcinoma, Basal Cell; Disease-Free Survival; Drug Eruptions; Equivalence Trials as Topic; Face; Fluorouracil; Humans; Imiquimod; Male; Photochemotherapy; Photosensitizing Agents; Skin Cream; Skin Neoplasms; Treatment Outcome | 2018 |
Two cases of erosive pustular dermatosis of the scalp occurring after topical 3.75% imiquimod for actinic keratoses.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Clobetasol; Dermatologic Agents; Drug Eruptions; Humans; Imiquimod; Keratosis, Actinic; Male; Scalp; Scalp Dermatoses; Treatment Outcome | 2019 |
IL-1R1 signaling facilitates Munro's microabscess formation in psoriasiform imiquimod-induced skin inflammation.
Topics: Abscess; Adjuvants, Immunologic; Aminoquinolines; Animals; Animals, Newborn; Chemokine CXCL1; Chemokine CXCL2; Dermis; Drug Eruptions; Epidermal Cells; Humans; Imiquimod; Interleukin-1alpha; Interleukin-1beta; Keratinocytes; Mice; Mice, Knockout; Neutrophils; Primary Cell Culture; Psoriasis; Receptors, Interleukin-1 Type I; Signal Transduction | 2013 |
Imiquimod, molluscum, and the need for a better “best pharmaceuticals for children” act.
Topics: Adjuvants, Immunologic; Administration, Cutaneous; Aminoquinolines; Child; Child, Preschool; Diffusion of Innovation; Drug Eruptions; Drug Industry; Female; Humans; Imiquimod; Male; Molluscum Contagiosum; Publication Bias; Randomized Controlled Trials as Topic; Treatment Failure; United States; United States Food and Drug Administration | 2013 |
Mechanism of pathogenesis of imiquimod-induced skin inflammation in the mouse: a role for interferon-alpha in dendritic cell activation by imiquimod.
Topics: Aminoquinolines; Animals; Antineoplastic Agents; Cytokines; Dendritic Cells; Drug Eruptions; Imiquimod; Membrane Glycoproteins; Mice, Inbred C57BL; Nitric Oxide; Nitric Oxide Synthase Type II; Toll-Like Receptor 7; Tumor Necrosis Factor-alpha | 2014 |
Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy.
Topics: Adult; Aminoquinolines; Anaphylaxis; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Drug Eruptions; Female; Guillain-Barre Syndrome; Humans; Imiquimod; Indoles; Melanoma; Middle Aged; Nivolumab; Programmed Cell Death 1 Receptor; Skin Neoplasms; Sulfonamides; Vemurafenib | 2013 |
Lichen planopilaris after imiquimod 5% cream for multiple BCC in basal cell naevus syndrome.
Topics: Alopecia; Aminoquinolines; Antineoplastic Agents; Basal Cell Nevus Syndrome; Drug Eruptions; Female; Head and Neck Neoplasms; Humans; Imiquimod; Lichen Planus; Middle Aged; Scalp; Skin Cream; Skin Neoplasms | 2015 |
Erythema multiforme induced by imiquimod 5% cream.
Topics: Adjuvants, Immunologic; Aged; Aminoquinolines; Drug Eruptions; Erythema Multiforme; Humans; Imiquimod; Male; Skin Cream | 2014 |
Hypertrophic and keloid scars after the application of 5% imiquimod cream: a report of 2 cases.
Topics: Adult; Aged; Aminoquinolines; Cicatrix, Hypertrophic; Dosage Forms; Drug Eruptions; Female; Humans; Imiquimod; Keloid; Male | 2014 |
Aldara®-induced skin inflammation: studies of patients with psoriasis.
Topics: Adjuvants, Immunologic; Administration, Cutaneous; Aminoquinolines; Drug Eruptions; Female; Humans; Imiquimod; Male; Middle Aged; Ointments; Psoriasis | 2015 |
Histologic features mimicking mycosis fungoides induced by imiquimod, 5%: a potential pitfall for dermatopathologists.
Topics: Adjuvants, Immunologic; Aged, 80 and over; Aminoquinolines; Drug Eruptions; Humans; Imiquimod; Keratosis, Actinic; Male; Mycosis Fungoides; Skin Diseases | 2014 |
Aldara-induced psoriasis-like skin inflammation: isolation and characterization of cutaneous dendritic cells and innate lymphocytes.
Topics: Aminoquinolines; Animals; Cell Separation; Cells, Cultured; Cricetinae; Dendritic Cells; Drug Eruptions; Female; Flow Cytometry; Imiquimod; Immunity, Innate; Lymphocytes; Male; Mice; Psoriasis; Rats; Skin | 2014 |
IMQ-induced skin inflammation in mice is dependent on IL-1R1 and MyD88 signaling but independent of the NLRP3 inflammasome.
Topics: Adjuvants, Immunologic; Aminoquinolines; Animals; Carrier Proteins; Cytokines; Drug Eruptions; Imiquimod; Inflammasomes; Membrane Glycoproteins; Mice; Mice, Knockout; Myeloid Differentiation Factor 88; NLR Family, Pyrin Domain-Containing 3 Protein; Receptors, Interleukin-1 Type I; Signal Transduction; Skin; Toll-Like Receptor 7 | 2015 |
Tumour necrosis factor-α plays a significant role in the Aldara-induced skin inflammation in mice.
Topics: Adjuvants, Immunologic; Administration, Cutaneous; Aminoquinolines; Animals; Biomarkers; Calgranulin A; Drug Eruptions; Imiquimod; Interleukins; Intracellular Signaling Peptides and Proteins; Mice, Inbred C57BL; Mice, Knockout; Ointments; Protein Serine-Threonine Kinases; Psoriasis; RNA, Messenger; Tumor Necrosis Factor-alpha | 2016 |
IMQ Induced K14-VEGF Mouse: A Stable and Long-Term Mouse Model of Psoriasis-Like Inflammation.
Topics: Aminoquinolines; Animals; Cytokines; Disease Models, Animal; Drug Eruptions; Imiquimod; Mice, Inbred Strains; Mice, Transgenic; Otitis; Psoriasis; Vascular Endothelial Growth Factor A | 2015 |
Successful treatment of multiple vemurafenib-induced keratoacanthomas by topical application of imiquimod cream: Confirmation of clinical clearance by dermoscopy.
Topics: Adjuvants, Immunologic; Administration, Cutaneous; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Drug Eruptions; Female; Humans; Imiquimod; Indoles; Keratoacanthoma; Melanoma; Skin Neoplasms; Sulfonamides; Treatment Outcome; Vemurafenib | 2016 |
Imiquimod-induced Psoriatic Erythroderma Treated with Infliximab.
Topics: Aged; Aminoquinolines; Antineoplastic Agents; Dermatitis, Exfoliative; Dermatologic Agents; Drug Eruptions; Female; Humans; Imiquimod; Infliximab | 2017 |
Reducing Flightless I expression decreases severity of psoriasis in an imiquimod-induced murine model of psoriasiform dermatitis.
Topics: Administration, Cutaneous; Aminoquinolines; Animals; Antibodies, Monoclonal; Antibodies, Neutralizing; Carrier Proteins; Cytoskeletal Proteins; Dermatitis; Disease Models, Animal; Drug Eruptions; Female; Humans; Imiquimod; Irritants; Male; Mice, Inbred BALB C; Microfilament Proteins; Middle Aged; Psoriasis; RNA, Messenger; Toll-Like Receptor 4; Trans-Activators | 2017 |
Monocyte-derived inflammatory Langerhans cells and dermal dendritic cells mediate psoriasis-like inflammation.
Topics: Adjuvants, Immunologic; Aminoquinolines; Animals; Dendritic Cells; Drug Eruptions; Gene Expression Regulation; Humans; Imiquimod; Inflammation; Interleukin-23; Langerhans Cells; Major Histocompatibility Complex; Membrane Proteins; Mice; Mice, Knockout; Monocytes; Psoriasis; Skin | 2016 |
BAY 11-7082 inhibits the NF-κB and NLRP3 inflammasome pathways and protects against IMQ-induced psoriasis.
Topics: Aminoquinolines; Animals; Apoptosis; Cytokines; Dermatologic Agents; Drug Eruptions; Drug Evaluation, Preclinical; Imiquimod; Inflammasomes; Male; Mice, Inbred C57BL; Mice, Knockout; NF-kappa B; Nitriles; NLR Family, Pyrin Domain-Containing 3 Protein; Psoriasis; RNA, Messenger; STAT3 Transcription Factor; Sulfones | 2017 |
Large genital ulcers in a patient with Behçet's disease associated with imiquimod cream treatment for external genital warts.
Topics: Adult; Aminoquinolines; Behcet Syndrome; Condylomata Acuminata; Drug Eruptions; Female; Humans; Imiquimod; Interferon Inducers; Skin Ulcer; Vulvar Diseases | 2008 |
Morbilliform exanthem induced by imiquimod in a patient with drug-related immunosuppression.
Topics: Adjuvants, Immunologic; Aminoquinolines; Drug Eruptions; Exanthema; Humans; Imiquimod; Immunocompromised Host; Male; Middle Aged; Pemphigoid, Bullous | 2009 |
Pemphigus-like lesions induced by imiquimod.
Topics: Aminoquinolines; Antineoplastic Agents; Carcinoma, Basal Cell; Drug Eruptions; Female; Humans; Imiquimod; Middle Aged; Pemphigus; Skin Neoplasms | 2009 |
[Imiquimod cream. A cream to use with precaution].
Topics: Administration, Topical; Adult; Aminoquinolines; Antineoplastic Agents; Carcinoma, Basal Cell; Condylomata Acuminata; Drug Eruptions; Female; Humans; Imiquimod; Keratosis, Actinic; Male; Skin Neoplasms; Treatment Outcome | 2010 |
[Erythema multiforme due to 5% imiquimod cream].
Topics: Adjuvants, Immunologic; Aged; Aminoquinolines; Drug Eruptions; Erythema Multiforme; Female; Humans; Imiquimod; Pharmaceutical Preparations | 2010 |
[Topical imiquimod for the treatment of anogenital warts in an infant].
Topics: Administration, Topical; Aminoquinolines; Antineoplastic Agents; Anus Diseases; Condylomata Acuminata; Drug Eruptions; Follow-Up Studies; Genital Diseases, Male; Hospitalization; Humans; Imiquimod; Infant; Inguinal Canal; Male; Skin; Skin Ulcer; Treatment Outcome | 2010 |
[Pityriasis rubra pilaris with focal acantholytic dyskeratosis during treatment with imiquimod 5% cream].
Topics: Acantholysis; Aminoquinolines; Antineoplastic Agents; Drug Eruptions; Humans; Imiquimod; Male; Middle Aged; Pharmaceutical Preparations; Pityriasis Rubra Pilaris | 2010 |
Severe systemic reaction to topical imiquimod.
Topics: Administration, Cutaneous; Aged; Aminoquinolines; Dehydration; Dizziness; Drug Eruptions; Female; Humans; Imiquimod; Keratosis, Actinic; Nausea; Severity of Illness Index; Vomiting | 2011 |
Cytokine dermatitis and febrile seizure from imiquimod.
Topics: Abdomen; Administration, Topical; Aminoquinolines; Child, Preschool; Cytokines; Drug Administration Schedule; Drug Eruptions; Drug Hypersensitivity; Female; Groin; Humans; Imiquimod; Interferon Inducers; Molluscum Contagiosum; Seizures, Febrile | 2012 |
Arbor cutis: hyperkeratotic plaque secondary to the use of imiquimod for the treatment of squamous cell carcinoma in situ.
Topics: Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Carcinoma in Situ; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Eruptions; Female; Forearm; Humans; Imiquimod; Keratosis; Skin Neoplasms | 2013 |
Localized pemphigus foliaceus induced by topical imiquimod treatment.
Topics: Administration, Cutaneous; Aminoquinolines; Antineoplastic Agents; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Diagnosis, Differential; Drug Eruptions; Face; Facial Dermatoses; Female; Humans; Imiquimod; Middle Aged; Pemphigus; Skin Neoplasms | 2004 |
Generalized exacerbation of psoriasis associated with imiquimod cream treatment of superficial basal cell carcinomas.
Topics: Administration, Topical; Aminoquinolines; Antineoplastic Agents; Carcinoma, Basal Cell; Drug Eruptions; Female; Humans; Imiquimod; Middle Aged; Psoriasis; Skin Neoplasms | 2006 |
A case of severe eczema following use of imiquimod 5% cream.
Topics: Adjuvants, Immunologic; Adult; Aminoquinolines; Condylomata Acuminata; Drug Eruptions; Eczema; Humans; Imiquimod; Male; Ointments; Penile Diseases | 2006 |
Generalized psoriasis induced by topical treatment of actinic keratosis with imiquimod.
Topics: Administration, Cutaneous; Aged; Aminoquinolines; Antineoplastic Agents; Drug Eruptions; Humans; Imiquimod; Keratosis; Male; Ointments; Psoriasis; Scalp Dermatoses | 2006 |
Topical imiquimod in the treatment of infantile hemangiomas: a retrospective study.
Topics: Administration, Cutaneous; Aminoquinolines; Antineoplastic Agents; Child, Preschool; Drug Eruptions; Facial Neoplasms; Female; Head and Neck Neoplasms; Hemangioma; Humans; Imiquimod; Infant; Infant, Newborn; Interferon Inducers; Male; Ointments; Remission Induction; Retrospective Studies; Severity of Illness Index; Skin Neoplasms; Treatment Outcome | 2007 |
Severe reaction to 5% imiquimod cream with excellent clinical and cosmetic outcomes.
Topics: Adjuvants, Immunologic; Administration, Topical; Adult; Aged; Aged, 80 and over; Aminoquinolines; Cheilitis; Drug Eruptions; Female; Humans; Imiquimod; Keratosis; Male; Middle Aged; Ointments; Time Factors; Treatment Outcome | 2007 |
Imiquimod 5% cream: a new treatment option for basal cell carcinoma.
Topics: Adjuvants, Immunologic; Aminoquinolines; Carcinoma, Basal Cell; CD3 Complex; Cytokines; Dose-Response Relationship, Drug; Drug Eruptions; Humans; Imiquimod; Interferon-gamma; Interleukins; Neoplasms, Fibroepithelial; Receptors, Cell Surface; Skin Neoplasms; Th1 Cells; Tumor Necrosis Factor-alpha | 2002 |